Arcturus Therapeutics In... (ARCT)
NASDAQ: ARCT
· Real-Time Price · USD
11.66
0.02 (0.17%)
At close: May 16, 2025, 3:59 PM
11.65
-0.09%
After-hours: May 16, 2025, 04:20 PM EDT
Arcturus Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|
| Grant Revenue | 13.92M | 157.75M | 244K |
| Grant Revenue Growth | -91.18% | +64550.82% | n/a |
| Collaboration Revenue Revenue | 138.39M | n/a | 205.75M |
| Collaboration Revenue Revenue Growth | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 11.31M | 12.38M | 13.28M | 11.42M | 14.85M | 11.69M | 13.38M | 13.22M | 13.76M | 11.86M | 12.49M | 10.99M | 10.73M | 10.81M | 10.86M | 10.04M | 9.74M | 9.03M | 5.57M | 4.42M | 4.19M | 1.79M | 3.88M | 3.46M | 3.53M | 3.44M | 3.81M | 8.23M | 5.1M | 2.65M | 1.65M | 2.09M | 1.18M | 1.29M | 1.21M | 1.4M | 1.46M | 1.32M | 1.18M | 1.2M | 1.29M |
| Selling, General, and Administrative Revenue Growth | -8.60% | -6.75% | +16.29% | -23.13% | +27.02% | -12.60% | +1.15% | -3.90% | +16.04% | -5.03% | +13.60% | +2.45% | -0.70% | -0.50% | +8.15% | +3.07% | +7.85% | +62.13% | +26.06% | +5.46% | +134.00% | -53.85% | +12.30% | -2.21% | +2.70% | -9.69% | -53.72% | +61.49% | +92.02% | +61.30% | -21.28% | +77.20% | -8.24% | +6.19% | -13.62% | -3.84% | +10.04% | +12.67% | -2.16% | -6.75% | n/a |
| Research and Development Revenue | 34.89M | 43.78M | 39.13M | 36.34M | 53.57M | 26.82M | 51.08M | 52.67M | 51.77M | 26.98M | 37.69M | 38.19M | 44.89M | 32.63M | 45.4M | 45.68M | 50.05M | 24.29M | 17.7M | 7.94M | 7.92M | 11.99M | 7.05M | 7.27M | 7.32M | 4.85M | 3.97M | 4.22M | 3.94M | 11.36M | 1.06M | 1.44M | 2.06M | 4.45M | 6.4M | 4.18M | 3.36M | 3.33M | 2.85M | 3.68M | 3.59M |
| Research and Development Revenue Growth | -20.30% | +11.87% | +7.68% | -32.16% | +99.77% | -47.50% | -3.02% | +1.74% | +91.87% | -28.41% | -1.31% | -14.93% | +37.57% | -28.12% | -0.62% | -8.73% | +106.09% | +37.22% | +122.80% | +0.34% | -33.99% | +70.06% | -2.97% | -0.75% | +51.10% | +22.12% | -6.06% | +7.21% | -65.30% | +972.33% | -26.61% | -29.95% | -53.68% | -30.52% | +53.04% | +24.39% | +0.81% | +16.89% | -22.54% | +2.59% | n/a |